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Abstract
Objective—To evaluate 24 hour urine exosome protein content changes among pregnant US 
subjects with diabetes and obesity during early pregnancy.
Methods—The exosome proteome content from 24 hour urine samples of pregnant subjects with 
gestational diabetes mellitus (GDM, N=8) and pre-gestational Type 2 diabetes (PGD, N = 10) 
were compared with control samples (CTRL, N = 10) obtained at week 20 of pregnancy. 
Differences in exosome protein load between groups was identified by liquid chromatography/
mass spectrometry, analyzed by linear regression in negative binomial distribution, visualized in 
MetaboAnalyst (version 3.0), and validated by western immunoblotting.
Results—At the 20th week of pregnancy, we identified 646, 734 and 856 proteins in exosomes 
from 24 hour urine samples of patients from the CTRL, GDM and PGD groups, respectively. S100 
calcium binding protein A9, damage associated molecular pattern (DAMP) signal, was found to be 
significantly increased in both GDM and PGD subjects. In GDM subjects the peptide counts for 
S100A9 protein independently correlated with maternal obesity and macrosomia of the newborn 
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infants. Early to late pregnancy developmental changes in the GDM group were shown to utilize 
pathways and protein expression levels differently from those in PGD or CTRL groups.
Conclusions—Urinary exosome proteomic analysis non-invasively provides insights into 
maternal changes during diabetic pregnancy. Exosome biomarkers early in pregnancy can be 
potentially used to better understand pathophysiologic mechanisms of diabetes at a cellular level, 
and to distinguish between gestational and pre-gestational diabetes at the pathway level. This 
information can aid intervention efforts to improve pregnancy outcomes in women with diabetes.
Keywords
Damage associated molecular pattern; Diabetic pregnancy; Exosome; Gestational diabetes; Urine 
exosomes; Proteomics; S100A9
Introduction
Diabetes during pregnancy increases the risk of poor pregnancy outcomes. Poorly controlled 
maternal diabetes may increase the risk of malformations involving multiple organ systems, 
such as fetal cardiac and spinal abnormalities during the first trimester and even fetal loss 
during the third trimester [1]. Renal glomerular filtration rate and plasma flow increase 
during normal pregnancy, leading to increases in proteinuria, glucosuria, and lower serum 
osmolality and sodium levels [2]. In pregnancies complicated by diabetes these changes may 
be exacerbated causing subclinical renal insufficiency in addition to the other unfavorable 
outcomes mentioned [3]. Pre-gestational diabetic (PGD) mice develop accelerated renal 
pathology [4], suggesting that stimuli that elicit benign responses in the non-diabetic 
pregnancies may lead to renal dysfunction or injury in diabetic pregnancies [5,6]. Further, as 
demonstrated by the collaborative perinatal project, the PGD mothers carry different risks of 
giving birth to malformed infants than do the GDM mothers [7]. Mechanisms underlying 
end organ damage or malformation and the maternal/fetal metabolic programing affecting 
the kidney function of the newborn still remain incompletely defined [8–11]. New tools that 
are noninvasive yet specific enough to examine the pathologic alterations in maternal 
diabetes during pregnancy are required to study clinically relevant sequelae specific to GDM 
or PGD phenotypes. We believe that urinary exosomes represent a noninvasive paradigm 
that potentially may be able to address phenotype-specific questions.
Exosomes are membrane bound biologically active nanovesicles released from every cell 
type [12,13]. They are formed by inward budding of late endosomes, producing 
Multivesicular bodies (MVBs). They are then released into the surrounding biofluid by 
fusion of MVBs with the plasma membrane [14]. The endocytic origin of exosomes and the 
cellular nature of their contents enable them to be recognized as a rich source of information 
on the status of the cells producing them. Because their contents significantly change in 
response to stress or injury [15] they are also potent mediators of intercellular 
communication [16]. Average human kidneys filter 1500–2000 liters of plasma on a daily 
basis to produce roughly 1.5 liters of urine. Together with the observation that urinary 
exosomes contain 3–5% of the total urinary proteins, exosomes represent enriched 
background information on the subject’s systemic status.
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Diabetic pregnancy is a stressor on multiple organs, including the kidney. Further, GDM is 
qualitatively a different type of stress compared to PGD [7]. Therefore, at an early time point 
during diabetic and normal pregnancy we sought to characterize urine exosome proteins 
from CTRL (n=10), PGD (n=10) and GDM (n=8) women. We also investigated pathway 
level differences between pre-gestational and gestational diabetes, as well as developmental 
changes from early to late pregnancy as reflected in their urine exosome proteomes.
Materials & Methods
Patient Selection
Singleton pregnancies who received prenatal care at the University of California San Diego 
Medical Center from 2011 to 2013 were consented to participate in the study. The study 
design and recruitment was reviewed and approved by the institutional review board. 
Informed consent for participation was obtained from all study participants. Inclusion 
criteria included pre-existing Type 2 diabetes or gestational diabetes. Diagnosis for 
gestational diabetes followed the criteria established by the California Sweet Success 
Program. This criterion includes at least one of the following: a first trimester HbA1c 
between 5.7–6.4% (39–46 mmol/mol), a fasting plasma glucose between 92–126 mg/dL, or 
a second trimester two hour glucose tolerance test with a fasting plasma glucose of greater 
than or equal to 92 mg/dL, one hour greater than or equal to 180 mg/dL, ora two hour 
plasma glucose greater than or equal to153 mg/dL [17]. Control samples were obtained from 
consenting women who did not have preexisting diabetes and screened negative for 
gestational diabetes. Study participants were required to collect a 24 hour urine sample at 20 
and 36 weeks gestation.
Demographics
Data was collected from a chart review. Information regarding diabetes management and 
control were obtained during first, second, and third trimesters, including HbA1c, fasting 
plasma glucose levels, diabetes medications (oral hypoglycemics and insulin), and any 
maternal medical complications. Fetal outcomes including ultrasound, estimated third 
trimester fetal weight, and birth weight were also collected.
Study design
Urine samples at the 20th week (early time point) of pregnancy from 8 GDM, 10 PGD and 
10 CTRL subjects were used for exosome isolation and proteomic analysis in replicates. A 
subset of these subjects that completed sample collection during 36th week of pregnancy (5 
GDM, 3 PGD and 4 CTRL pregnancy subjects) were separately analyzed to evaluate 
differences between the 20th and 36th week. Proteomic data were analyzed using negative 
binomial distribution as well as MetaboAnalyst (version 3.0) and validated by Western 
immunoblotting where applicable.
Urine Sampling and Processing
24 hour urine samples were collected spanning 2 days. The first void of Day 1 was not 
collected. All voids were collected from the second void on Day 1 to the first void on Day 2, 
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including all nocturnal voids. During collection the samples were kept on ice or refrigerated. 
After 24 hours collected urine samples were centrifuged at 3000 × g for 30 min. The pH of 
the resulting supernatant was adjusted to 7.0, aliquoted, and frozen at −70 °C until further 
analysis.
Exosome preparation and proteomic analysis
Exosomes from frozen pregnancy urine samples were prepared using an in-house protocol 
developed based on the solvent exclusion principle using polyethylene glycol (PEG)- 
induced precipitation, as described in our recent publication [18]. One-dimensional SDS-
PAGE of the exosome proteins prior to in-gel trypsinization was performed.
Data Processing and Statistical Analysis
In all analyses, p ≤0.05 was considered statistically significant. Log transformation of raw 
data were performed before the tests. Analyses including Student’s t-tests, Partial-Least 
Squares Discriminant Analysis (PLS-DA) and Variable Importance in Projection (VIP) were 
performed with the MetaboAnalyst 3.0 (www.metaboanalyst.ca) web portal [19]. Negative 
binomial generalized linear regression models were fit using the statistical software R 
version 3.1.2.20
PLS-DA and VIP were used both for the classification and significant feature selection [19] 
with a False Discovery Rate (FDR) of ≤10 % to filter protein candidates for western 
immunoblotting validation. Negative binomial generalized linear models were fit to 
determine significant differences in protein counts between CTRL, GDM, and PGD subjects 
utilizing the raw count data and estimating gene-wide size factors and estimated dispersion-
mean relationship via the methods outlined in Anders and Huber in the R package DESeq2 
[21]. Significance was reported based on a filtered FDR-adjusted p-value.
Western Immunoblotting and Quantification
Antibody against S100 A9 was purchased from Proteintech Group, Inc., (Chicago, IL, 
USA). HRP-conjugated secondary antibody was from GE Life Sciences (Piscataway, NJ, 
USA). SDS-PAGE gels (with 10% acrylamide) were used to resolve 100 μg of protein from 
exosomes of normal and diabetic pregnancy urine samples. Immunoblotting and 
quantification with Image J software (NIH) was done using methods described in our 
previous publications [22] and plotted using Graph Pad Prism software (San Diego, CA, 
USA).
Results
Patient Demographics Show Significant Differences between Diabetic and Non-Diabetic 
Pregnancy Subject Phenotypes
We studied 24 hour urine samples from 28 mothers: 10 non-diabetic subjects that served as 
controls (CTRL) and 18 with diabetes (8 gestational, GDM and 10 pregestational, PGD) 
recruited from UC San Diego Reproductive Medicine clinics. Clinical disease data on 6 
GDM, 7 PGD and 6 CTRL mothers was collected. Newborn birth weight in PGD averaged 
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3155.3 gms as compared to 3884.8 gms in GDM group. Medication regimens were different 
between the two groups: while all 7PGD subjects required medication, only 2 GDM subjects 
required medication. The level of diabetes control between the PGD and GDM groups was 
different. For this study, HbA1c ≥7% (53 mmol/mol) was considered a marker for poorly 
controlled disease. Accordingly, our data indicate that 5 of the 7 PGD patients were poorly 
controlled, while all of the GDM patients were well controlled. The minimum diagnostic 
criteria based on HbA1c are 5.7% (39 mmol/mol) for GDM and 6.5% (48 mmol/mol) for 
PGD. In our cohort, the average HbA1c was 6.0% (42 mmol/mol) for GDM and 7.1% (54 
mmol/mol) for PGD subjects, showing an average increase of only 0.053% above the 
diagnostic criteria for GDM, but an increase of 0.09% above the diagnostic criteria for the 
PGD group. Thus GDM group subjects had better controlled disease than PGD subjects, 
possibly due to the shorter time course of GDM as compared to PGD (Table 1).
Average maternal BMI and neonate head circumference were similar between the GDM and 
PGD groups (Table 2). None of the PGD neonates in our cohort was macrosomic (average 
birth weight 3155.3±664.5 gms). Of the 6 GDM neonates, 3 were macrosomic (4485±86.07 
gms) and 3 were normal (3285±337 gms). Thus phenotypically, both the mother and the 
newborn infant in the GDM group were different from that in the PGD group.
The Urinary Exosome Protein Content is Different in Diabetic versus Normal Pregnancy 
Subjects
Urine exosome proteomic data from an early time point of pregnancy (24 hour urine samples 
from week 20) showed that 1103 proteins were identified with a spread of 645 CTRL 
proteins, 855 GDM proteins and 733 PGD proteins in each subject of the group.475 proteins 
were common to all three groups (Figure S1). Tables S1–S5 document the individual protein 
identity of each of the groups. These protein data show differences in the non-diabetic versus 
diabetic pregnancy urine exosomes’ protein signatures, and further differences between 
GDM and PGD subjects at an early pregnancy time point.
To further delineate semi-quantitative differences between groups we used Negative 
Binomial Distribution to perform linear regression of the expression data of 1103 proteins. 
CTRL vs GDM analysis showed 70 proteins to be significantly different with S100 calcium-
binding protein A9 (S100A9) the most different between the groups. (Table S1, FDR<10%). 
Similar analysis on CTRL vs PGD groups showed 77 proteins to be significantly different, 
with S100A9 as one of the 7 proteins reaching FDR<10% (Table S2).
We used MetaboAnalyst suite to visualize the proteomic data. Partial Least Squares 
Discriminant (PLSD) analysis (Figures 1A–1C) showed a clear separation between CTRL 
and GDM proteins early in pregnancy. To determine which proteins contribute to this 
discrimination we conducted the Variable Importance in Projection (VIP) analysis (Figure 
1D). Table S3 shows that 107 proteins contributed to this discrimination between CTRL and 
GDM groups, with a VIP score of >1.5, and S100A9 topped this list with a VIP score of 
7.7.A similar analysis between CTRL and PGD groups showed clear distinction between 
protein expressions in the 2 groups and S100A9 with the top VIP score of 4.09 (Table S4).
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S100A9 Protein Upregulation in Early Pregnancy Urine Exosome of Diabetic Subjects is 
Validated by Western Immunoblotting
We validated the statistically significant upregulation of S100A9 protein in diabetic urine 
exosomes by western immunoblotting analysis. Equal amounts (50 μg) of protein from each 
exosome sample was used, (Figure 2A, 2B) showing significant S100A9 upregulation in 
diabetic exosome. However, all diabetic patients did not uniformly show S100A9 
upregulation. We therefore sought to further determine if the demographic feature 
differences between subjects of the same group correlate with the relative abundance of this 
protein as denoted by its peptide count.
S100A9 Protein Peptide Count Data Correlates with Obesity and Macrosomia Differently in 
GDM versus PGD subjects
The average urinary exosome load of S100A9 peptide count for the PGD group was 
22.25±37.89 (N=10) while the GDM had an average peptide count of 23.63±34.7 (N=8). 
Both were significantly different from the CTRL subject peptide count of 1.15±2.39 (N = 
10) (p=0.0065, GDM vs CTRL and p=0.0174, PGD vs CTRL), which also closely tracked 
with the western blot data.
The average S100A9 peptide count was significantly different in the PGD and GDM 
subjects (7.4±13.43 versus 29.08±38.78, p=0.0209). When level of control of disease within 
the group was considered, PGD patients with well controlled disease have a lower average 
peptide count(0.25±0.5) compared with the poorly controlled group of PGD patients. It is 
noteworthy that both of these averages are less than the GDM group average.
GDM mothers with macrosomicneonates of had an average peptide count of 32.67±54.4 
while GDM mothers of non-macrosomic neonates had an average peptide count of 
25.5±17.85. Whereas this peptide count difference is likely less significant, it does illustrate 
a higher maternal peptide count for macrosomic neonates. Interestingly, a significantly 
higher rate of macrosomia in GDM than in PGD was observed (p=0.0002).
Lastly, we considered BMI. 6 of the 7 PGD patients and 4 of the 6 GDM patients were 
obese. Peptide count average of obese PGD patients was 6.25±12.44, while that of a single 
non-obese PGD patient was 0. In the GDM group, peptide average of obese patients was 
42.5±37.53 and only 2.25±2.87 for non-obese patients. In the non-diabetic group, the 
peptide average of the obese subjects was 11.5±4.04 and only 1.67±1.51 for non-obese 
subjects. This strong trend (p=0.0585) demonstrates that peptide count is higher in pregnant 
obese women than in pregnant non-obese women.
Urine Exosome Protein Content Changes from Early to Late Pregnancy Proceed via 
Different Pathways in CTRL versus PGD versus GDM
Further, we sought to examine how progression of pregnancy from an early time point to a 
later time point is reflected in the urine exosome proteins and pathways in these three 
groups. We performed a nested analysis on urine exosomes from 4 CTRL, 5 GDM and 3 
PGD subjects that completed the 36th week collection in addition to the 20th week samples.
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We observed considerable differences between exosome proteomes of early versus late 
pregnancy. For the 20th and 36th week samples respectively, 357 and 268 proteins (CTRL), 
460 and 396 proteins (GDM) and 369 and 352 proteins (PGD) were identified. Thus the 
number of proteins identified in urine exosome generally decreased from early to late 
pregnancy. Groupwise analyses of the 20th and 36th week samples showed that the number 
of unique proteins identified reduced 5-fold in CTRL, roughly 2-fold in GDM and only 
slightly decreased in PGD groups (Figures S2A and S2B).
Thus, although the number of total pregnancy proteins identified was the highest in the 
GDM group (GDM>PGD>CTRL with 530,470 and 377 proteins respectively), within a 
group, the newer proteins identified during later pregnancy was CTRL < GDM <PGD with 
20, 70 and 101 proteins respectively.
In addition, the protein pathways predominantly contributing to changes in progression of 
pregnancy from week 20 to week 36 were different in each group (Table S5, Figures S3A–
S3C). We observed differences even in the extent to which a protein expression changed in 
one group versus the other (Δ1 =Protein1 NSAFWeek20 – Proteinl NSAFWeek36). Thus, Δ 1 
(for a given protein) for CTRL was different from Δ 1 for GDM, which in turn was different 
from Δ 1 for PGD group.
Discussion
Urine comprises at least two distinct exosome populations: exosomes that are produced by 
pre-glomerular organs such as brain and muscle that are filtered from plasma into urine, and 
those that are produced by the kidney tubular cells distal to glomerular filtration. Urine 
exosome proteins represent only 3% of the whole urine proteome [23] and their cellular 
nature allows for the strong likelihood that this 3% contains cell- and cell-state specific 
markers derived from both renal and pre-renal organs. Given that every living surface is 
shown to use these bio-active nanoparticles for intercellular communication, [24] urine 
exosomes potentially have a systemic level representation, and their analysis provides 
clinically relevant information in describing a disease phenotype such as diabetes during 
pregnancy. Two recent exosome proteomics analysis from (a) Pisitkun, et al. show 295 
distinct proteins at least 22 of which have been implicated in various kidney and systemic 
abnormalities [25] and (b) Zhou, et al. show the utility of exosomes as a source of kidney 
physiology biomarkers in AKI subjects [26].
In this report, we examined the difference in urine exosome protein content of diabetic and 
non-diabetic pregnancy subjects. In all, we found that 1103 proteins were identifiable from a 
total of 28 urine exosome samples of nondiabetic and diabetic subjects. Using three 
independent methods, namely negative binomial distribution for linear regression analysis, 
partial least squares discriminant analysis, and variable importance in projection analysis of 
the proteomic data, we have shown that the calcium binding protein S100 A9 is significantly 
upregulated in both pregestational as well as gestational diabetic pregnancies. S100A9 
upregulation in diabetics was validated by western immunoblotting. We also showed that the 
peptide number of this protein independently correlates with macrosomia in the newborn 
infant as well as maternal obesity, although to a different extent in the GDM versus PGD 
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groups. Though the mechanism of S100A9 upregulation in diabetes/obesity and its clinical 
significance needs to be established, other recent studies [27–29] have demonstrated 
S100A9 upregulation in diabetes or obesity, further supporting our finding.
S100A9 upregulation as a biomarker of inflammatory processes and immune response is 
gaining fast ground. S100A9 heterotetramerizes with S100A8 to form calprotectin,which 
has a plethora of intracellular and extracellular functions.It is predominantly localized in the 
cytoplasm but is translocated to the cytoskeleton and cell membrane upon elevation of 
intracellular calcium level, and gets secreted to extracellular space to amplify innate immune 
response by acting as an endogenous Danger-Associated Molecular Pattern (DAMP) that 
promotes inflammation [30]. To our knowledge, this report is the first study showing 
S100A9 elevation in the urinary exosomes of human subjects with obese/diabetic pregnancy. 
Given its ability to induce neutrophil chemotaxis and adhesion, a role for S100A9 in 
exosome vesicle trafficking cannot be ruled out. If so, it would be interesting to address 
whether S100A9 would play a role in increased exosome production in diabetic milieu.
This study has numerous strengths. The 24-hour urine sample collection design lends itself 
to reduced variation and is more representative of the phenotype. Collection of samples at 
two time points from the same individuals allows for quantification of intra-subject 
variability. Additionally, by virtue of their lipid lamellar structure, exosomes serve to 
transport hydrophobic proteins, so the analysis is not limited to hydrophilic proteins only. 
One limitation of this study is its small sample sizes. The S100A9 upregulation should be 
confirmed in a larger population, with subjects that are more tightly grouped together and 
matched with respect to age, gravidity, and ethnicity. Additionally, the pre-gestational 
diabetic group did not include any patients with Type 1 diabetes, and therefore the results of 
this study are limited in their application to Type 1 diabetics and further studies in this 
population are needed. In our PGD population the date of diabetic diagnosis, and therefore 
duration of their disease, was not collected. As a result we were unable to analyze the data 
with regards to duration of disease. Further, the PGD vs GDM difference in S100A9 peptide 
count also needs to be verified in a larger population. It appears that when the data within 
the PGD group peptide count is considered, higher peptide count is associated with poorer 
diabetes control. Possibly by extending the time points of sample collection to include the 
4th-8th week of pregnancy and 6 weeks after childbirth, this finding can be further validated. 
By developing a list of plausible risk-stratifiers, non-diabetic and/or non-obese pregnant 
women at risk for developing diabetes can potentially benefit from these studies.
Finally, we used 1d gel electrophoresis to resolve the exosome proteins prior to LC/MS-MS 
analysis, which resulted in identification of 1103 proteins overall. If we had conducted direct 
exosome protein trypsinization instead of following this method, perhaps the number of 
identified proteins might have increased. In our experience, exosomes cargo contains non-
full length peptides as well, and has the potential to confound the analysis. By following the 
gel electrophoresis method, we ensured that we only compare full length protein differences 
between groups.
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Conclusion
In this study, we summarize our initial findings from diabetic pregnancy urine exosome 
proteomic analyses. We used exosomes from 24 hour urine samples of diabetic pregnancy 
subjects obtained during the 20th week of pregnancy and compared them with exosomes 
from nondiabetic pregnancy subjects. Our data show major alteration to calcium-handling 
pathways and cellular-danger signal pathways between groups. The major finding of this 
study is that the DAMP protein S100A9 sorts into exosomes, and in diabetics this exosomal 
sorting is upregulated. The exosomal load of this protein correlates with not only maternal 
obesity but also macrosomia of the new born infant. Further, developmental changes from 
week 20 to week 36 in GDM and PGD phenotypes employ different protein pathways.
Given that maternal diabetes during human pregnancy alters the quality of life of both the 
mother and the newborn after childbirth, and considering the non-invasive nature of urinary 
exosome collection, processing and analysis of 24 hour urine samples is an attractive 
platform to study diabetes during pregnancy and its consequences.
Work from the Knepper group shows that many important renal proteins (e.g. aquaporins, 
polycystins and podocyn) are shed in the urine exosome. [25; 31] Our current report adds 
S100A9 to this group of functionally important proteins to be identified in urine exosomes. 
Our findings, together with other studies in pancreatic cancer tissue, saliva, and serum 
suggest that the upregulation of S100A9 DAMP signal is a common and valid biomarker of 
inflammatory processes and immune response. This report potentially forms the preliminary 
level basis for future studies wherein the pharmacologic and therapeutic potential of S100A9 
and related pathways could be utilized to impart personalized care to a pregnant woman with 
diabetes.
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Figure 1A: 
PGD vs. controlconcentration-based proteomic measurements: PLSDA separation using 
protein NSAF measurements in the urine exosome of Pre-Gestational Diabetes Mellitus 
(PGD,n = 10) vs Control subjects (CTRL,n = 10). Lack of overlap between the two groups 
of exosome proteins signifies clear separation of PGD from CTRL.
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Figure 1B: 
PGD vs. Control variable importance in projection plot: Urinary exosome proteins identified 
by PLS-DA in a descending order of importance. The graph represents relative contribution 
of proteins to the variance between the PGD and CTRL urine exosomes. The green and red 
boxes on the right indicate whether the protein concentration is increased (red) or decreased 
(green) in the exosome of the PGD urine vs. CTRL urine samples. Similar to analysis in 
Figure 1b, S100A9 is the top protein (VIP score of >4.5).
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Figure 1C: 
GDM vs. control concentration-based proteomic measurements: Two-dimensional (2D) 
partial least squares discriminant analysis (PLSDA) separation using protein normalized 
spectral abundancy factor (NSAF) concentration-based proteomic measurements in the urine 
exosome of Gestational Diabetes Mellitus (GDM, n=8) vs Control subjects (CTRL, n = 10). 
Clear separation of GDM from CTRL is observed.
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Figure 1D: 
GDM vs. control variable Importance In projection plot: The graph represents relative 
contribution of proteins to the variance between the GDM and CTRL urine exosomes at 
week 20 of pregnancy. High value of VIP score for a protein indicates greater contribution of 
the protein to the separation of groups. The green and red boxes on the right indicate 
whether the protein concentration is increased (red) or decreased (green) in the exosome of 
the GDM urine vs. CTRL urine samples. For higher n value, a VIP score of 1.5 is considered 
to enable discrimination between 2 phenotypes. Even with the low n (=10) per group that is 
employed in this study, the VIP score of the top 3 proteins is higher than 3. S100 calcium 
binding protein A9 is the top protein with a VIP score of >7.
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Figure 2A: 
Immunoblotting of pregnancy urine exosome for S100A9 protein. Lanes 1–3: control; lanes 
4–6: GDM; lanes 7–9: PGD.
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Figure 2B: 
Quantification of S100A9 from immunoblots in A (control, n=3; GDM, n=3, PGD, n=3). 
Data are means ± SEM. p<0.05 pregnancy urine exosome S100A9 GDM versus CTRL; 
PGD versus CTRL.
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Table 1:
Patient Demographics.
Variable PGD, N=7 GDM, N=6 Control, N=6 P value
Age 30.9±8.1 30.7±7.1 33.2±5.8 0.84
Race/Ethnicity
White 0 0 3 0.04
Black 2 1 0 0.76
Asian 0 1 0 0.56
Hispanic 4 4 2 0.13
Other 2 0 1 0.21
Weight (kg) 87±17.2 89.1±20.4 75.6±13.4 0.48
BMI (m/kg2) 33.9±4.3 33.6±6.6 27.6±6.8 0.2
HgBAIC (%) First Trimester 9.2±1.7 6±0.28 5.3±0.17 0.0003
Second Trimester 7.3±1.2 5.9±0.35 NA 0.09
Third Trimester 6.7±0.8 6 NA 0.48
Fasting Plasma Glucose (mg/dL) 92.4±18.3 92±18.3 74±12.5 0.3
75 mg 2 Hour Oral Glucose Tolerance Test Glucose Level (mg/dL) NA 170.5±79.9 85.5±21.9 NA
Medications
Oral 2 2 0 0.13
Insulin 6 0 0 0.13
Pre-eclampsia 1 0 0 0.04
Gestational Hypertension 2 0 0 0.47
Retinopathy 0 0 0 NA
Chronic Hypertension 3 0 0 0.2
Nephropathy 0 0 0 NA
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Table 2:
Neonatal Outcomes.
Variable PGD, N=7 GDM, N=6 Control, N=6 P value
Gestational Age (weeks, days) 37 weeks 5 days 38 weeks 3 days 38 weeks 2 days 0.863
Birth Weight (grams) 3155±697 3555±232 3173±285 0.666
Birth Length (cm) 50.1±3 51.1±2.7 49.6±1.6 0.672
Head circumference (cm) 33.6±2.3 34.5±1 34±1.4 0.729
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